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S U M M A R Y
Objective: The objective of the current study was to detect Staphylococcus aureus colonization and the
presence of superantigen in atopic dermatitis (AD) in Egyptian patients, and to determine its effect on
disease severity and serum interleukin (IL)-4 levels.
Methods: Swabs were taken from the skin of 30 patients with AD. S. aureus isolates were screened for the
presence of genes of exotoxins with superantigen properties by multiplex PCR. Serum IL-4 was
determined by ELISA. The rate of S. aureus colonization and the presence of superantigen were correlated
with disease severity and IL-4 level.
Results: Twenty-six of 30 patients (87%) were colonized by S. aureus, and 14 of the 26 (54%) patients were
colonized with toxigenic strains. The most frequent superantigen gene present in S. aureus isolates was
that coding for staphylococcal enterotoxin B (SEB), followed by both staphylococcal enterotoxin C (SEC)
and toxic shock syndrome toxin-1 (TSST-1) genes. The mean ‘severity scoring in AD’ (SCORAD) score of
AD patients colonized with S. aureus harboring superantigen genes (74  8) was signiﬁcantly higher than
that in those colonized with S. aureus isolates without superantigen genes (56  6) (p < 0.001). Serum IL-4
levels followed the same pattern.
Conclusions: S. aureus may play an important role as an aggravating factor in AD patients. Reducing the
colonization of atopic skin by S. aureus is therefore the best way to reduce superantigen-induced allergic
skin inﬂammation.
 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Staphylococcus aureus is a commensal organism that colonizes
up to 50% of humans. The organism most often colonizes the
anterior nares and, from there, may colonize other body surfaces,
including other mucous membranes and damaged skin.1 S. aureus
causes a wide variety of human illnesses, including scalded skin
syndrome, toxic shock syndrome (TSS), and necrotizing pneumo-
nia.1 The ability of S. aureus to cause human disease depends on the
production of cell-surface adhesins, antiphagocytic factors, and
secreted exotoxins, whose functions appear to be both securing
nutrients for the microbes and delaying the functions of the
immune system.2 Among the secreted factors is a large family of
superantigen exotoxins. Staphylococcal superantigens include
staphylococcal enterotoxins (SE) and toxic shock syndrome
toxin-1 (TSST-1).3 Superantigens are deﬁned by their ability to
stimulate cytokine release from both T cells and macrophages.4* Corresponding author. Tel.: +20 167220520.
E-mail address: nahed_gomaa@yahoo.com (Nahed I.M. Gomaa).
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accounts for the most severe manifestations of superantigen-
mediated illnesses.3,4
Atopic dermatitis (AD) is a T cell-mediated skin disease that can
signiﬁcantly compromise quality of life, because patients experi-
ence sleep disturbances, social embarrassment, and emotional
distress.5 S. aureus infection contributes to the worsening of skin
inﬂammation in AD. These organisms have been shown to produce
superantigens, including SEA, SEB, SEC, SED, and TSST-1.6
Furthermore, superantigens have been demonstrated to induce
corticosteroid resistance of T cells in vitro.7 This could contribute to
difﬁculty in the management of AD, because topical corticosteroids
are the most common medication used for treatment of AD.
However, the presence of superantigens in S. aureus isolates that
colonize the skin of patients with AD has not been examined
previously in Egyptian patients. Furthermore, the correlation
between the presence of superantigen and disease severity has not
been elucidated.
This study was conducted in order to assess the colonization of
AD patients with S. aureus and to determine by multiplex PCR
whether superantigens (enterotoxins A, B, C, and D, and TSST-1)ses. Published by Elsevier Ltd. All rights reserved.
Table 1
Nucleotide sequences, gene locations, and anticipated sizes of PCR products10
Gene Oligonucleotide sequence
(50–30)
Location
within
gene
Size of
ampliﬁed
product (bp)
sea GGTTATCAATGTGCGGGTGG 349–368 102
CGGCACTTTTTTCTCTTCGG 431–450
seb GTATGGTGGTGTAACTGAGC 666–685 164
CCAAATAGTGACGAGTTAGG 810–829
sec AGATGAAGTAGTTGATGTGTATGG 432–455 451
CACACTTTTAGAATCAACCG 863–882
sed CCAATAATAGGAGAAAATAAAAG 492–514 278
ATTGGTATTTTTTTTCGTTC 750–769
femA AAAAAAGCACATAACAAGCG 1444–1463 132
GATAAAGAAGAAACCAGCAG 1556–1575
tst ACCCCTGTTCCCTTATCATC 88–107 326
TTTTCAGTATTTGTAACGCC 394–113
Table 2
Baseline demographic characteristics of the study group
Variable Number (%)
Number of patients 30
Men, n (%) 16 (53%)
Women, n (%) 14 (47%)
Age, mean (range) 10 (5–26) years
Mean disease duration 4 years
Urban, n (%) 20 (67%)
Rural, n (%) 10 (33%)
SCORAD, mean  SD 64  12
SCORAD, severity scoring in atopic dermatitis score; SD, standard deviation.
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determine the correlation between the presence of superantigen
and the severity of the disease and the level of interleukin (IL)-4
production.
2. Materials and methods
2.1. Study subjects
This study included 30 AD patients who presented to the
Dermatology and Venereology Clinic, Suez Canal University
Hospital in Ismailia, Egypt. AD was diagnosed according to the
major and minor diagnostic criteria proposed by Haniﬁn and
Rajka.8 There was no selection of patients by age, gender, area of
residence, or severity of lesions. The control group comprised 30
healthy, non-atopic, and unrelated volunteers, matched for age and
sex. They were enrolled in the study if their skin tested negative
and after excluding a history of allergic conditions. Ethical approval
to conduct the study was given by Suez Canal University Hospital
and consent was obtained from all subjects before inclusion in the
study.
All subjects included in this study were subjected to a complete
clinical history followed by clinical examination. The clinical
severity of AD was determined according to the ‘scoring atopic
dermatitis’ index (SCORAD), which is a scoring system combining
extent, severity, and subjective symptoms of AD.9 The following
patients were excluded from the study: those with a severe fungal
infection or other skin diseases that might disturb the diagnosis
and treatment; those with the concomitant presence of another
severe systemic infection; pregnant or lactating women; those
with severe heart, liver, or kidney diseases and mental diseases;
those with diseases affecting immune function, such as diabetes,
AIDS, malignant tumors, and autoimmune diseases; and those
under treatment with systemic corticosteroids or immune-
suppressive agents in the last 4 weeks, or under treatment with
topical antibiotics in the last 2 weeks or with systemic antibiotics
in the last 4 weeks.
2.2. Isolation of S. aureus from skin
Sterile swabs were immersed in saline, and then in different
lesions on the same patient. All swabs were sent to the laboratory
within 30 min. The swabs were plated onto blood agar. Colonies
were grown for 24 h at 37 8C. S. aureus was identiﬁed by testing
typical colonies as regards pigmentation and colony size by Gram
staining (Gram-positive, cluster-forming cocci), positive catalase
activity, and positive coagulase activity.
2.3. PCR for superantigen genes testing
A multiplex PCR assay was used for the detection of genes for
staphylococcal enterotoxins A to D and TSST-1. Detection of femA was
used as an internal positive control. The following strains were used
as positive controls in this study: ATCC-SEA 13565, ATCC-SEB 14458,
ATCC-SEC 19095, 90-S-1025-SED, and 92-S-1344-TSST-1. Total DNA
was isolated from 0.5 ml of brain–heart infusion broth culture grown
overnight for all the bacterial strains isolated in the study, using the
GeneElute bacterial genomic DNA kit (Sigma, St. Louis, MO, USA), in
accordance with the manufacturer’s guidelines. The primer
sequences used in the multiplex PCR are listed in Table 1.10
The multiplex PCR conditions were as follows: The master mix
of components contained 200 mM deoxynucleoside triphosphates;
5 ml of 10 reaction buffer (100 mM Tris–HCl (pH 8.3), 500 mM
KCl), 1.5 mM MgCl2, 20 pmol (each) of sea, seb, sec, tst, and femA
primers, 40 pmol of sed primer, 2.5 U of Taq DNA polymerase
(AmpliTaq DNA polymerase; Perkin-Elmer), and 10 to 1000 ng oftemplate DNA. The volume of this mix was adjusted to 50 ml with
sterile water. DNA ampliﬁcation was carried out in a Perkin-Elmer
thermocycler with the following thermal cycling proﬁle: an initial
denaturation at 94 8C for 5 min was followed by 35 cycles of
ampliﬁcation (denaturation at 94 8C for 2 min, annealing at 57 8C
for 2 min, and extension at 72 8C for 1 min), ending with a ﬁnal
extension at 72 8C for 7 min.10
2.4. Detection of serum IL-4
Serum IL-4 was measured with an ELISA (R&D System, Inc.,
Minneapolis, MN, USA) in accordance with the manufacturers’
instructions.
2.5. Statistical analysis
Data were presented in the form of tables and graphs when
appropriate. The t-test was used to test the correlation between the
severity of AD and S. aureus colonization and the presence of
superantigen. p-Values of less than 0.05 were considered signiﬁ-
cant.
3. Results
This study included 30 AD patients who presented to the
Dermatology and Venereology Clinic, Suez Canal University
Hospital. Baseline demographic characteristics of the study group
are shown in Table 2. Sixteen patients were male and 14 were
female. The age of the study group ranged between 5 and 26 years,
with a mean age of 10 years (standard deviation of  4). The mean
duration of the disease was 4 years (standard deviation of  2.7).
Twenty patients lived in urban areas, while the rest (10 patients) lived
in rural areas. The mean SCORAD score of the patients was 64  12.
Twenty-six patients (87%) were found to be colonized with S.
aureus in their skin lesions, while four patients were not colonized
with S. aureus (p < 0.005) (Figure 1). Fourteen of the 26 S. aureus
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Figure 1. Rate of colonization of the skin of atopic dermatitis patients with
Staphylococcus aureus with and without superantigens.
Figure 3. Types of superantigen produced by Staphylococcus aureus strains isolated
from skin lesions of atopic dermatitis patients.
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superantigen properties, while the remaining 12 strains (46%)
did not show the presence of superantigen (Figure 1).
Multiplex PCR was performed to test for the presence of the
different superantigen genes in the bacterial isolates (as shown in
Figure 2). The most likely superantigen genes present in S. aureus
isolated from the lesional skin of AD patients are shown in Figure 3.
The most frequent superantigen gene found in S. aureus isolates
was the gene for SEB (eight patients), followed by the genes for
both SEC and TSST-1 (four patients each), while the least frequent
genes were those for SEA and SED (one patient each). Moreover, of
the 14 toxigenic S. aureus strains isolated, 11 showed only one type
of superantigen gene, while three strains were found to have more
than one type of superantigen gene (two isolates had SEB and SEC
genes and one isolate had SEB, SEC, and TSST-1 genes).
The mean SCORAD score of AD patients colonized with
superantigen-producing S. aureus (74  8) was signiﬁcantly higher
than that of AD patients colonized with S. aureus isolates without
superantigen production (56  6), as shown in Figure 4 (p < 0.001).Figure 2. Multiplex PCR ampliﬁcation products for the Staphylococcus aureus
superantigen genes. Lane M, 100-bp ladder (Bethesda Research Laboratories Inc.,
Gaithersburg, MD, USA); lanes 1–6, PCR amplicons. Lane 1, sea plus femA; lane 2, seb
plus femA; lane 3, sec plus femA; lane 4, sed plus femA; lane 5, see plus femA; lane
6, tst plus femA; lane 7, negative control.Serum IL-4 was assessed in all AD patients. It was signiﬁcantly
elevated in all patients (mean 35.6 pg/ml) compared to controls
(mean 12.9 pg/ml) (p < 0.001), but it was higher in those harboring
superantigen-producing S. aureus versus AD patients with S. aureus
not producing superantigen (p < 0.05) (Figure 5).
4. Discussion
As a result of an altered skin structure characterized by skin
barrier dysfunction and inﬂammation of the upper dermis, S.
aureus has a peculiar ability to colonize the skin of patients with
AD, and is consistently found in eczematous skin lesions in these
patients.11 S. aureus superantigens play an important role in the
natural course of AD.12–14 In this study, the types of superantigen
present in S. aureus isolated from the skin of Egyptian AD patients
are described, as well as their relationship with the severity of the
disease.
We found 87% of AD patients to be colonized with S. aureus in
their lesional skin. This is in agreement with the results of other
studies that have described the colonization of AD patient skin
with S. aureus, but with different isolation rates ranging from 60%
to 100%.6,15–20 This variation in the prevalence of S. aureus in AD
patients may be ascribed to the fact that approximately 60% of
individuals are colonized only intermittently by S. aureus and
therefore S. aureus is not always detected at the time of
examination.21 Moreover one of the important factors of this
discrepancy is the great variation in the clinical severity of the AD
in each study, as was highlighted in the study done by David and
Cambridge; they reported that S. aureus was isolated in 53% of
patients with mild AD and in 100% with moderate and severe AD.22
Our study results conﬁrm the important role of colonization
with S. aureus as an aggravating factor in AD, as there was a
signiﬁcant correlation between the severity of the disease
(SCORAD) and S. aureus skin colonization in our patients. These
data are consistent with previous reports in which the high
prevalence of S. aureus colonization in the lesional skin of patients
with AD was signiﬁcantly correlated with eczema severity, and it
has been determined that bacterial colonization is an important
factor aggravating skin lesions.18,21 It has been shown that AD may
be aggravated by the direct biological action of bacteria or their
products, or by an immunological reaction to bacterial antigens or
superantigens.23
In our study, 14 of the 26 S. aureus strains isolated from AD
patients (54%) showed the presence of exotoxins with super-
antigen properties, while the remaining 12 strains (46%) did not
show this. Previous studies have shown that 30–60% of S. aureus
strains isolated from patients with AD secrete exotoxins with
superantigenic properties, e.g., staphylococcal enterotoxins A, B, C,
and D, and TSST-1.6,24–27 Silva et al. documented that toxigenic
strains were isolated from the skin of all AD patients (100%) in their
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Figure 4. The mean SCORAD score of atopic dermatitis patients with superantigen-producing Staphylococcus aureus versus atopic dermatitis patients with superantigen non-
producing Staphylococcus aureus.
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Figure 5. Serum interleukin (IL)-4 level of atopic dermatitis patients with
superantigen-producing Staphylococcus aureus versus atopic dermatitis patients
with superantigen non-producing Staphylococcus aureus.
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most patients we detected only one toxin gene, however two toxin
genes were found in two patients and three toxin genes in one
patient. Therefore a single strain may have the ability to produce
different toxins. The SEB gene was the most frequently found in the
isolates analyzed in our study, followed by the genes for SEC and
TSST-1, then SEA and SED. The proportion of toxin-producing
strains and the frequency of certain toxins differ between
studies.17,27,28
An explanation for this diversity in superantigen production by
S. aureus in AD patients is the severity of the disease and the site of
the skin involved or where the swab was taken from. Yagi et al.
reported the detection rate of S. aureus that produces superantigen
from different skin areas in AD patients and found the following:
40.7% in the non-lesional area, 61.7% in the dry-lesional area, and
75.3% in the exudative-lesional area.29
There are multiple lines of evidence supporting the concept that
superantigens play a role in the pathogenesis of AD. From a clinical
standpoint, more than 50% of patients with AD have S. aureus
isolates that secrete at least one superantigen.17 Additionally the
application of the prototypic superantigen, staphylococcal entero-
toxin B, to unaffected atopic or healthy skin induces eczematous
skin changes of erythema, induration, and mononuclear cell
inﬁltration.30 The T-cell inﬁltrate in AD skin has been shown to be
characterized by T-cell receptor V-b speciﬁcities of the super-
antigen-producing S. aureus found in AD skin.25 Further clinical
observations supporting a role for superantigens in the pathogen-
esis of AD include the observation that treatment of AD with a
combination of corticosteroids and antibacterials is often more
effective than corticosteroid therapy alone.31
In addition, this study demonstrated that AD patients colonized
with S. aureus harboring superantigen genes had a signiﬁcantly
increased severity of the disease as measured by the SCORAD index
compared to patients colonized with S. aureus isolates without
superantigen genes present. This is in accordance with several
studies that have demonstrated that S. aureus-derived exotoxins
with superantigen activity contribute signiﬁcantly to disease
severity as quantiﬁed by the SCORAD score.18,25,32,33
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higher in patients with AD than in normal controls. This shows that
cytokines are involved in the pathogenesis of AD.34 IL-4 was also
higher in those harboring superantigen-producing S. aureus versus
AD patients with S. aureus not producing superantigen. This result
is consistent with other studies that have shown that peripheral
blood mononuclear cells from children with AD35 and from
adults36,37 have enhanced IL-4 production in response to SEB and
TSST-1. This might indicate that other important immunologic
mechanisms include the role of superantigens in promoting T
helper-2 skin inﬂammation, leading to arming of mast cells and
basophils with IgE directed to superantigen. With persistent S.
aureus colonization, superantigens are secreted into the skin,
causing degranulation and histamine release and thus contributing
to persistent skin inﬂammation. The increased IL-4 in AD patients
(the T helper-2 (Th2) cytokine milieu of AD skin) increases
adherence of S. aureus to atopic skin, as shown by Cardona et al.,
who demonstrated in the mouse model of allergic skin inﬂamma-
tion that S. aureus binds signiﬁcantly more to skin sites with
increased IL-4 and IL-13 expression and also that healthy skin
treated with IL-4 shows increased bacterial binding.31 Thus, a
vicious circle ensues in which the increased IL-4 in AD skin
enhances superantigen-producing S. aureus adherence, then these
superantigens induce Th2 skin inﬂammation and a further increase
in IL-4 levels, leading to persistent S. aureus colonization.
In conclusion, this article has attempted to bring to light the
importance of bacterial superantigens in the pathogenesis of AD in
Egyptian patients and the deleterious effect of S. aureus coloniza-
tion and superantigens on atopic skin. Superantigens have been
demonstrated to induce corticosteroid resistance of T cells in
vitro.7 This could contribute to the difﬁculty in the management of
AD, because topical corticosteroids are the most common
medication used for the treatment of AD.
Reducing the avidity of atopic skin for S. aureus is therefore the
best way to reduce superantigen-induced allergic skin inﬂamma-
tion, hence other options need to be explored.
The presence of other superantigens should be further studied
to obtain a more comprehensive proﬁle in Egyptian AD patients.
Furthermore, genotyping of isolated strains to cluster them in
different clones and to study the relationship between the isolates
would be of future interest.
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